Iniparib (BSI-201)

Names

[ CAS No. ]:
160003-66-7

[ Name ]:
Iniparib (BSI-201)

[Synonym ]:
Iniparib (BSI-201)
4-Iodo-3-nitrobenzamide
Benzamide, 4-iodo-3-nitro-
Iniparib
BSI-201

Biological Activity

[Description]:

Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

[Related Catalog]:

Signaling Pathways >> Cell Cycle/DNA Damage >> PARP

Signaling Pathways >> Epigenetics >> PARP

Research Areas >> Cancer

[Target]

PARP1

[In Vitro]

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells[1]. Iniparib (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1[2]. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes[3].

[Cell Assay]

For nine day cell proliferation assay, MDA-MB-436 and MDA-MB-231 cells are plated at 2000 and 500 cells/well respectively in a 96-well plate and treated with veliparib, cmpd-A, cmpd-C, Iniparib or Iniparib-met at 0, 0.0001, 0.01,0.1, 1 or 10 μM for nine days. For five day cell proliferation assay, MDAMB-231 and MDA-MB-436 cells are plated at 1000 and 4000 cells/well respectively in a 96-well plate and treated with Iniparib or Iniparib-met at 0. 0.1, 0.3, 1, 3 or 10 μM in the presence of 0, 1.8, 3.75, or 7.5 µM BSO for 5 days. DLD1+/+ and DLD1-/- cells are plated at 1000 cells/well in a 96-well plate and treated with TMZ at 0, 0.003, 0.01, 0.03, 0.1, 0.3 or 1 mM in the presence of 0, 0.005, 0.05, 0.5, or 5 µM veliparib, or Iniparib for five days. After treatment, cell titer glow is carried out[1].

[References]

[1]. Liu X, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23.

[2]. Ma W, et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5.

[3]. Yin S, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 2017 Aug 17;12(8):e0183578.

[Related Small Molecules]

Talazoparib | XAV-939 | MK-4827(Niraparib) | Veliparib (ABT-888) | Rucaparib (AG-014699) phosphate | PJ34 HCl | Pamiparib | Rucaparib camsylate | E-7449 | AZD2461 | G007-LK | NMS-P118 | A-966492 | AG14361 | JW55

Chemical & Physical Properties

[ Density]:
2.1±0.1 g/cm3

[ Boiling Point ]:
344.8±32.0 °C at 760 mmHg

[ Molecular Formula ]:
C₇H₅IN₂O₃

[ Molecular Weight ]:
292.031

[ Flash Point ]:
162.3±25.1 °C

[ Exact Mass ]:
291.934479

[ PSA ]:
88.91000

[ LogP ]:
1.71

[ Appearance of Characters ]:
white to beige

[ Vapour Pressure ]:
0.0±0.8 mmHg at 25°C

[ Index of Refraction ]:
1.696

[ Storage condition ]:
room temp

[ Water Solubility ]:
DMSO: soluble5mg/mL, clear

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H319

[ Precautionary Statements ]:
P305 + P351 + P338

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
22-36-43

[ Safety Phrases ]:
26

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2924299090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2924299090

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%